Joint Session of the ESR and EORTC

ESR/EORTC - Current status of breast cancer imaging in clinical trials

1

05:00Wolfgang Gerhard Kunz, Munich / DE

2

25:00Daniela Elena Oprea-Lager, Nijmegen / NL

3

25:00Frédéric Lecouvet, Brussels / BE

4

25:00Lioe-Fee De Geus-Oei, Leiden / NL

ESR/EORTC-1

5 min

Chairperson's introduction

Wolfgang Gerhard Kunz, Munich / Germany

ESR/EORTC-2

25 min

Oligometastatic breast cancer screening in clinical trials

Daniela Elena Oprea-Lager, Nijmegen / Netherlands

To learn which imaging modalities provide a more accurate diagnosis of oligometastatic disease.
To become familiar with the current guidelines.
To understand the use of modern imaging modalities in oligometastatic breast cancer.

ESR/EORTC-3

25 min

New imaging technologies for advanced breast cancer

Frédéric Lecouvet, Brussels / Belgium

To highlight the value of whole-body MRI as a highly accurate modern imaging tool for metastatic screening in breast cancer.
To illustrate the specific indications of WB-MRI in advanced breast cancer, from diagnosis of metastasis to response assessment.
To understand the respective roles of WB-MRI and PET/CT and how a patient-specific approach to metastatic disease is currently necessary.

ESR/EORTC-4

25 min

Optimal use of FDG-PET/CT in breast cancer: new EANM/SNMMI guidelines, endorsed by ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA

Lioe-Fee De Geus-Oei, Leiden / Netherlands

To learn about the evidence-based recommendations to perform 2-[18F]FDG PET/CT in the initial staging, in assessing response to therapy and in assessing recurrence.
To become familiar with the new guidelines.
To understand the role of 2-[18F]FDG-PET/CT in NST breast cancer.

ESR/EORTC-5

10 min

Panel discussion